<?xml version="1.0" encoding="ISO-8859-1"?>
<brand>
	<title><![CDATA[VOTRIENT]]></title>
	<colour><![CDATA[#ff6600]]></colour>
	<logo>votrient.png</logo>
	<rootVideo>camera.mov</rootVideo>

	<menu>
		<!-- Advanced Renal Cell Carcinoma (aRCC) -->
		<item id="0"><![CDATA[ADVANCED RENAL CELL CARCINOMA (aRCC)]]></item>
			<item id="0.0"><![CDATA[COMPARZ STUDY DESIGN]]></item>
			<item id="0.1"><![CDATA[COMPARABLE EFFICACY TO SUBITINIB]]></item>
			<item id="0.2"><![CDATA[DIFFERENTIATED SAFETY PROFILE FROM SUBITINIB]]></item>
			<item id="0.3"><![CDATA[LOWER IMPACT ON QoL THAN SUNITINIB]]></item>
			<item id="0.4"><![CDATA[PISCES STUDY DESIGN]]></item>
			<item id="0.5"><![CDATA[PREFERRED OVER SUNITINIB IN THE PISCES STUDY]]></item>
		
		<!-- Advanced Soft Tissue Sarcoma (aSTS) -->
		<item id="1"><![CDATA[ADVANCED SOFT TISSUE SARCOMA (aSTS)]]></item>
			<item id="1.0"><![CDATA[PHASE III DATA IN SECOND-LINE aSTS]]></item>
			<item id="1.1"><![CDATA[PFS IMPROVEMENT VS. PLACEBO]]></item>
			<item id="1.2"><![CDATA[CONSISTENT BENEFIT ACCROSS SUBTYPES]]></item>
			<item id="1.3"><![CDATA[WELL-ESTABLISHED SAFETY PROFILE]]></item>
			<item id="1.4"><![CDATA[MAINTAINS HRQoL VS. PLACEBO]]></item>
			
		<!-- Once-Daily Oral Dosing -->
		<item id="2"><![CDATA[ONCE-DAILY ORAL DOSING]]></item>
		
		<!-- Prescribing Information -->
		<item id="3"><![CDATA[PRESCRIBING INFORMATION]]></item>
		
	</menu>
</brand>